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Aims: Unimolecular peptides targeting the receptors for glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (GLP-1/GIP co-ago-
nist) have been shown to outperform each single peptide in the treatment of obesity
and cardiometabolic disease in preclinical and clinical trials. By combining physiologi-
cal treatment endpoints with plasma proteomic profiling (PPP), we aimed to identify
biomarkers to advance non-invasive metabolic monitoring of compound treatment
success and exploration of ulterior treatment effects on an individual basis.
Materials and methods: We performed metabolic phenotyping along with PPP in
body weight-matched male and female diet-induced obese (DIO) mice treated for
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21 days with phosphate-buffered saline, single GIP and GLP-1 mono-agonists, or a
GLP-1/GIP co-agonist.
Results: GLP-1R/GIPR co-agonism improved obesity, glucose intolerance, non-
alcoholic fatty liver disease (NAFLD) and dyslipidaemia with superior efficacy in both
male and female mice compared with mono-agonist treatments. PPP revealed
broader changes of plasma proteins after GLP-1/GIP co-agonist compared with
mono-agonist treatments in both sexes, including established and potential novel bio-
markers for systemic inflammation, NAFLD and atherosclerosis. Subtle sex-specific
differences have been observed in metabolic phenotyping and PPP.
Conclusions: We herein show that a recently developed unimolecular GLP-1/GIP co-
agonist is more efficient in improving metabolic disease than either mono-agonist in
both sexes. PPP led to the identification of a sex-independent protein panel with the
potential to monitor non-invasively the treatment efficacies on metabolic function of
this clinically advancing GLP-1/GIP co-agonist.
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1 | INTRODUCTION
Bariatric surgery is the most effective treatment option to correct
severe obesity and non-alcoholic fatty liver disease (NAFLD), to improve
type 2 diabetes (T2D) and to reduce cardiometabolic risk.1–3 However,
these surgeries are invasive and not applicable to the broad patient pop-
ulation. Hence, new drugs safely mimicking surgery-induced metabolic
benefits are urgently needed. Unimolecular peptides targeting the
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) receptor (GLP-1/GIP co-agonist) are currently in clini-
cal development for the treatment of obesity and diabetes.4,5 Their effi-
cacy to improve body weight, glucose handling and lipid metabolism
translates from rodent models of obesity to non-human primates and
humans outperforming best-in class GLP-1 monotherapies.4–6
Preclinical and clinical assessment of new drug candidates requires
cost- and time-intensive metabolic testing and in case of metabolic dis-
eases such as diabetes and NAFLD risky and highly invasive procedures
such as hyperinsulinaemic-euglycaemic clamps and liver biopsies. Drug
development would benefit from non-invasive biomarkers monitoring
therapeutic efficacy and disease progression.7 Particularly suitable for this
approach is blood because of the fact that proteins from almost every cell
and tissue are in circulation. Recent advances in mass spectrometry (MS)-
based plasma proteome profiling (PPP) enabled system-wide analyses of
plasma proteome changes under pathophysiological conditions.8,9 In
patients with obesity undergoing Roux-en-Y gastric bypass (RYGB), PPP
revealed that systemic inflammation and lipid transport are the major
remodelled processes by this weight loss intervention.10 An in-depth
evaluation of plasma proteome changes after treatment with clinically
advancing incretin-based peptide mimetics has not been performed yet.
This approach may point to unidentified mechanisms of action and iden-
tify new cardiovascular (CV) and metabolic health biomarkers, which are
urgently needed to stratify patient groups and to assess drug efficacy
early on in preclinical and early clinical stages.7
As approximately 80% of patients undergoing bariatric surgery
are women,11 we evaluated the metabolic efficacy of a GLP-1/GIP
co-agonist in female diet-induced obese (DIO) mice in comparison
with male DIO mice. This is of specific interest as some pharmacologi-
cal treatments entail a different spectrum of efficacy in women.12,13
Herein, we use a recently developed long-acting acylated GLP-1/
GIP co-agonist with balanced activity at the receptors for GLP-1 and
GIP.6 An α-aminoisobutyric acid residue at position 2 of the
unimolecular co-agonist prevents dipeptidyl peptidase IV (DPP4) deg-
radation, while the C-terminal extension improves solubility and phar-
macokinetics.6 We show that treatment with this GLP-1/GIP co-
agonist lowers body weight and improves glucose handling and lipid
metabolism to a larger extend than mono-agonists and with compara-
ble efficacy in both sexes. MS-based PPP revealed that GLP-1/GIP
treatment was more efficacious than either mono-agonist to reduce
inflammatory proteins and lipid transport proteins similar to RYGB in
humans. Despite sex-specific plasma proteome differences, we identi-
fied 10 proteins that are downregulated by GLP-1/GIP treatment in
both sexes and correlate with systemic metabolic benefits. Thus,
these proteins may be suitable to monitor non-invasively the drug
responses in preclinical and clinical studies.
2 | MATERIALS AND METHODS
2.1 | Animals and diet
Eight-week old female C57BL/6J mice (Charles River Laboratories,
Sulzfeld, Germany) were fed a high-fat, high-sugar diet (HFD)
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comprising 58% kcal from fat (D12331; Research Diets, New Bruns-
wick, NJ, USA) to induce DIO. For matching of body weight, age-
matched male mice were switched from regular chow to HFD at the
age of 33 weeks. This diet regimen was chosen as HFD-fed male mice
more rapidly gain body weight relative to female mice.14 Mice were
double-housed and maintained at 22 ± 2C, 55 ± 10% relative humid-
ity and a 12-h light/dark cycle with free access to food and water. At
the age of 37 weeks, DIO male (n = 30) and female mice (n = 28) were
randomly assigned to treatment groups matched for body weight and
fat mass.
All procedures were approved by the local Animal Use and
Care Committee and the local authorities of Upper Bavaria, Ger-
many in accordance with European and German animal welfare
regulations.
2.2 | Compound synthesis
The synthesis, purification and characterization of the fatty-acylated
GLP-1/GIP co-agonist as well as the pharmacokinetics-matched fatty-
acylated (palmitic acid C16:0) GLP-1 and GIP mono-agonists was
described previously in detail and was used without any further chem-
ical modification or change in formulation.6
2.3 | Rodent pharmacological and metabolism
studies
At the start of the study, body weight-matched obese male and female
mice were randomized by body weight and fat mass to either vehicle,
GIP, GLP-1 or GLP-1/GIP agonist treatment. Mice were treated with
daily subcutaneous injections (5 μL/g body weight) in the middle of the
light phase for 21 consecutive days at a dose of 10 nmol/kg/day. Body
weight and food intake was measured daily. Whole-body composition
(fat and lean mass) was measured via nuclear magnetic resonance tech-
nology (EchoMRI, Houston, TX, USA). Fasting blood glucose and intra-
peritoneal glucose tolerance (ipGTT) was determined after a 6-h fast at
study day 14 and 20 h after the last injection. For the ipGTT, fasted ani-
mals were injected intraperitoneally with 2 g glucose per kg body
weight. Blood glucose was subsequently measured at time points 0, 15,
30, 60 and 120 min using a handheld glucometer (FreeStyle).
2.4 | Biochemical analysis
Tail blood before ipGTT was collected after a 6-h fast using EDTA-
coated microvette tubes (Sarstedt) and immediately chilled on ice.
Mice were killed using CO2 after a 4-h fast and at least 16 h after
the last vehicle or compound injection. Sac blood was mixed with
EDTA and immediately kept on ice. Plasma was separated by centri-
fugation at 5000 g at 4C for 10 min. Levels of insulin (Crystal Chem,
Elk Grove Village, IL, USA) were measured following the manufac-
turer's instructions. The homeostatic model assessment of insulin
resistance (HOMA-IR) was used to determine insulin sensitivity. Total
plasma cholesterol (Thermo Fisher Scientific, Waltham, MA, USA)
was measured following the manufacturer's instructions. For lipopro-
tein separation, samples were pooled and analysed in a fast-
performance liquid chromatography gel filtration as described previ-
ously.15 Liver samples were fixed in 4% (w/v) neutrally buffered for-
malin, embedded in paraffin and cut into 3 μm slices for haematoxylin
and eosin staining. Stained tissue sections were scanned with an
AxioScan. Z1 digital slide scanner (Zeiss, Jena, Germany). Images were
evaluated using the commercially available image analysis software
Definiens Developer XD 2 (Definiens AG, Munich, Germany) as previ-
ously described.16 A specific rule set was defined to detect and quan-
tify the lipid vacuoles of the hepatocytes based on morphology, size,
pattern, shape, neighbourhood and special colour features. The calcu-
lated parameter was the ratio of total area of lipid vacuoles per whole
tissue section.
2.5 | Gene expression analysis
Gene expression profiling in the liver was performed in mice treated
with compounds for 21 consecutive days. For tissue collection, mice
were fasted for 4 h and treated with compounds at least 16 h before
tissue collection. Total RNA was isolated using RNeasy Kit (Qiagen,
Hilden, Germany) according to the manufacturer's instructions. cDNA
synthesis was performed with QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany) according to the manufacturer's instruc-
tions. Liver gene expression was profiled with quantitative real-time
reverse transcription-polymerase chain reaction using SYBR Green
with validated primers. The relative expression of the selected hepatic
genes was normalized to the reference gene peptidyl-prolyl cis-trans
isomerase b (Ppib). The following primers were used: Abcg5 forward
50-GTACATCGAGAGTGGCCAGA-30, Abcg5 reverse 50-CTGTGTATC
GCAACGTCTCG-30; Apoe forward 50-GATCAGCTCGAGTGGCAAA
G-30, Apoe reverse 50-TAGTGTCCTCCATCAGTGCC-30; Cyp3a11
forward 50-CTCTCACTGGAAACCTGGGT-30 , Cyp3a11 reverse 50-TC
TGTGACAGCAAGGAGAGG-30; Cyp8b1 forward 50-CAGCGGACAA
GAGTACCAGA-30, Cyp8b1 reverse 50-TGGATCTTCTTGCCCGACTT
-30; Ldlr forward 50-TCAGACGAACAAGGCTGTCC-30 , Ldlr reverse
50-CCATCTAGGCAATCTCGGTCTC-30; Lipc forward 50-ATGTGGGG
TTAGTGGACTGG-30, Lipc reverse 50-TTGTTCTTCCCGTCCATGG
A-30; Lrp1 forward 50-AACCTTATGAATCCACGCGC-30, Lrp1 reverse
50-TTCTTGGGGCCATCATCAGT-30; Pcsk9 forward 50-CACCCTGG
ATGCTGGTATCT-30 , Pcsk9 reverse 50-GACCTCTTCCCTGGCTTCTT
-30; Ppib forward 50-GCATCTATGGTGAGCGCTTC-30, Ppib reverse
50-CTCCACCTTCCGTACCACAT-30; Sqle forward 50-TGTTGCGGAT
GGACTCTTCT-30, Sqle reverse 50-GAGAACTGGACTGGGGTTGA-30.
2.6 | Statistical analyses
Statistical analyses were performed using GraphPad Prism8. The
Kolmogorov-Smirnov test was used to assess for normality of
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residuals. We used the Brown-Forsythe test to assess for the equality
of group variances. Significance among different treatment groups
and time points was determined by two- or one-way analysis of vari-
ances (ANOVA) followed by Tukey's post hoc analysis. Two-way
ANOVA was used when the influence of time and treatment was
examined. We used Kruskal-Wallis test followed by Dunn's multiple
comparison test to determine statistical significance when normality
of residuals was not given. In the case of only two groups, the
unpaired Student two-tailed t-test was used to detect significant dif-
ferences. A Grubbs test (α < .05) was used to detect significant out-
liers, which were then excluded from the subsequent statistical
analysis and figure drawing. P < .05 was considered statistically signifi-
cant. All results are mean ± SEM unless otherwise indicated.
2.7 | Plasma proteome profiling
At the end of study, plasma was obtained from mice that were fasted
for 4 h before sample collection and at least 16 h after the last vehicle
or compound injection. Plasma sample preparation8,17 and measure-
ment with high-pressure liquid chromatography and MS as well as the
analysis of MS raw files was reported previously.17
2.8 | Bioinformatics analysis
Bioinformatics analysis was performed in the Perseus platform18 and
R scripts. We filtered for proteins with 70% data completeness in at
least one experimental group and replaced the missing values by
drawing random samples.17 From originally 591 identified peptides,
we obtained a protein matrix of 563 peptides that were uniquely clas-
sified to a specific protein in male and female DIO mice, which was
used for subsequent data analysis. Signal intensities were log2 trans-
formed. A protein matrix with log2 imputed protein intensities for all
samples can be found in Table S1. The study was assessed according
to Geyer et al.19 regarding individual sample quality (Figure S1) and
significant bias in group comparisons (Figure S2). Because of overall
low sample contamination, no sample was excluded from downstream
analysis. We used the limma package20 with its voom method21 for
linear modelling and to find differentially regulated proteins between
two treatment groups. We used a P-value cut-off P < .01 for down-
stream analysis unless otherwise noted. Differentially regulated pro-
teins were assessed with a global correlation matrix to test for
erythrocyte lysis, platelet contamination or coagulation as their ori-
gin19 (Figure S3). Importantly, only very few differentially regulated
proteins cluster in one of these panels. This indicates that most
highlighted proteins derive from a treatment effect. We used
Enrichr22,23 and manual search for pathway and functional allocation
of the identified differentially regulated proteins. We filtered for pro-
teins of the inflammation system by including the following keywords:
complement, coagulation, chemotaxis, cytokine, inflammation, inflam-
matory, immune, immunity, defence response and membrane attack
complex.
2.9 | Data availability
The MS proteomics data have been deposited with the ProteomeXchange
consortium via PRIDE with the identifier PXD012056.
3 | RESULTS
3.1 | Glucagon-like peptide-1/glucose-dependent
insulinotropic polypeptide decreases body weight and
hyperglycaemia with equal efficiency in both sexes
Because of the slower progression of DIO in female mice, we delayed
the onset of HFD feeding in male mice to achieve study cohorts mat-
ched for body weight and age for the adequate assessment of
co-agonist-induced weight loss efficacy. Age-matched male and
female mice were fed a HFD for 4 and 29 weeks, respectively.
Despite similar body weight (Figure S4A), body fat mass was higher in
female relative to male DIO mice (Figure S4B), whereas lean tissue
mass was higher in male DIO mice (Figure S4C).
Similar to previous reports,6 treatment with GLP-1/GIP decreased
the body weight of male DIO mice (Figure 1A) primarily by reducing fat
mass (Figure 1B) and to a greater extent relative to the activity matched
GLP-1 and GIP mono-agonists. Inhibition of food intake was similar
between male DIO mice treated with GLP-1 and GLP-1/GIP,
suggesting that GLP-1/GIP also promotes weight loss via food-intake
independent effects (Figure 1C). In females, the GLP-1/GIP-induced
weight loss was similarly greater relative to treatment with either
mono-agonist (Figure 1D). Interestingly, in female DIO mice the supe-
rior effect of GLP-1/GIP to induce greater body weight loss relative to
GLP-1 alone emerged earlier relative to male DIO mice (day 15 vs. 19;
Figure 1A and 1D). The weight loss in female DIO mice was mainly
because of a loss of fat with only minor changes in lean tissue mass
(Figure 1E). While food intake inhibition was similar between male DIO
mice treated with GLP-1/GIP or GLP-1 (Figure 1C), we see in females a
greater inhibition of food intake by GLP-1/GIP relative to treatment
with GLP-1 (Figure 1F), although compound-induced weight loss was
comparable in both sexes (Figure S5A,B). Treatment with the acylated
GIP analogue alone at the given dose of 10 nmol/kg did not reduce
body weight or food intake in both sexes (Figure 1A and 1C).
GLP-1/GIP additionally improved fasting glucose levels and glu-
cose tolerance in male and female DIO mice (Figure S6A,B,E,F). Partic-
ularly in males, GLP-1 and GLP-1/GIP reduced fasting insulin levels
and fasting HOMA-IR, indicating improved insulin sensitivity
(Figure S6C,D). In females, only GLP-1/GIP but not the respective
monotherapies improved HOMA-IR, with subtle effects on already
low fasting insulin levels (Figure S6G,H). Chronic treatment with GIP
improved glucose tolerance in both sexes (Figure S6A,B,E,F), without
changes in fasting insulin levels (Figure S6C,G) or improving insulin
sensitivity determined by HOMA-IR (Figure S6D,H). Collectively,
GLP-1/GIP improves body weight and glucose handling with equal
efficacy in both sexes and with superior potency relative to the
respective single peptide mono-agonists.
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3.2 | Glucagon-like peptide-1/glucose-dependent
insulinotropic polypeptide treatment attenuates
hypercholesterolemia and non-alcoholic fatty liver
disease in both sexes
GLP-1/GIP co-agonism decreased fasting plasma cholesterol levels in
male and female DIO mice more efficiently compared with either
mono-agonist (Figure 2A and 2E). In males, the decrease in plasma
cholesterol by GLP-1/GIP resulted primarily from a reduction in low-
density lipoprotein (LDL) cholesterol, with only subtle changes of
high-density lipoprotein (HDL) (Figure 2B). GLP-1 treatment also
reduced LDL cholesterol in males, but to a lesser extent relative to
treatment with the co-agonist (Figure 2B). In females, GLP-1/GIP but
not the mono-treatments reduced plasma LDL levels, and both GLP-1
and GLP-1/GIP increased HDL (Figure 2F). Both, GLP-1 and GLP-1/GIP
improved NAFLD in both sexes, as indicated by reduced liver weights
and a decrease of the hepatic lipid area (Figure 2C-E,H-J). Moreover,
hepatic expression of proteins regulating cholesterol- (e.g. Sqle) and bile
acid (e.g. Cyp8b1) synthesis were downregulated after GLP-1/GIP treat-
ment (Figure S7A and S7B). This effect was more pronounced in male
DIO mice compared with female DIO mice potentially because of
reduced baseline expression of these genes in female DIO mice com-
pared with male DIO mice (Figure S7C). Thus, GLP-1/GIP improves
hypercholesterolemia and NAFLD in both sexes and with greater
potency relative to treatment with GIP or GLP-1 alone.
3.3 | Shotgun proteomics identifies sex-specific
differences in plasma
We next compared the plasma proteome of vehicle-treated DIO mice
to examine sex-specific differences in the untreated diseased (obese)
state, a question that to our knowledge has not been addressed previ-
ously. One-dimensional principal components analysis was sufficient
to separate plasma from male and female DIO mice demonstrating
substantial differences between sexes (Figure S8A; a list of all proteins
is given in Table S3). Sixty-two proteins were increased in male DIO
mice relative to female DIO mice, of which 33 were associated with
the complement system and inflammation (Figure S8B,C). Previously
it was shown that female mice and women have significantly lower
complement activity and plasma levels of complement components
relative to their male counterparts by measuring specific proteins
(e.g. C5, C6, C7, C8, C9).24,25 These sex-specific differences were con-
firmed and extended in our study of DIO male and female mice mat-
ched for body weight by undirected and unbiased PPP.
Apolipoproteins Apod and Apoa1, both constituents of the HDL
(A) (B) (C)
(D) (E) (F)
/ / / /Vehicle Acyl-GIP (10 nmol/kg) Acyl-GLP-1 (10 nmol/kg) Acyl-GLP1/GIP (10 nmol/kg)
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F IGURE 1 Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) treatment reduces obesity to a larger extent
relative to GLP-1 and GIP mono-agonists but with equal efficiency in diet-induced obese male and female mice. Male mice: A, percentage body
weight; B, change of body composition; and C, cumulative food intake. Female mice: D, percentage body weight; E, change of body composition;
and F, cumulative food intake. Mice were treated daily with either vehicle [n (female) = 7, n (male) = 7], acyl-GIP [10 nmol/kg; n (female) = 7, n
(male) = 8], acyl-GLP-1 [10 nmol/kg; n (female) = 7), n (male) = 7] or acyl-GLP-1/GIP [10 nmol/kg; n (female) = 7, n (male) = 8] via subcutaneous
injections for 21 consecutive days. Changes in body composition reflect changes from study day 0 to 21. Data represent means ± SEM. **P < .01,
***P < .001, determined by two-way ANOVA comparing vehicle with the acyl-GLP-1/GIP co-agonist. #P < .05, ##P < .01 determined by two-way
ANOVA comparing acyl-GLP-1 with the acyl-GLP-1/GIP co-agonist. ANOVA was followed by Tukey post hoc multiple comparison analysis to
determine statistical significance
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particle, were increased in males (Figure S8C). Components of LDL
particles, such as Apoc1, Apoc3, Apoc4 and LDL were slightly
increased in male compared with female DIO mice (P < .05; Table S3).
These results are consistent with the observation that total plasma
cholesterol, HDL and LDL levels are increased in male relative to
female DIO mice (Figure 2A, 2B, 2F and 2G). Among the differentially
expressed proteins, we also observed high levels of major urinary pro-
teins (Mup2, Mup3, Mup17) in male DIO mice (Figure S8C). Mup pro-
teins are carrier of pheromones in the blood and secreted by urine with
an increased abundance in male mice.26 This shows that PPP captured
inherent sex-specific differences between male and female DIO mice.
In plasma of female DIO mice, we found increased protein levels
of aldolase B (Aldob), sorbitol dehydrogenase (Sord), aspartate amino-
transferase [or glutamic-oxaloacetic transaminase (Got1)], serum amy-
loid P component (Apcs), Dpp4, leucine aminopeptidase 3 (Lap3),
NADP-dependent malic enzyme (Me1) and glutamyl aminopeptidase
(Enpep) (Figure S8D). Got1 is already used in the clinic as a regular
determined biomarker for liver diseases in humans.27 Aldob, Sord,
Apcs, Dpp4, Lap3, Me1 and Enpep were recently described as novel
markers for NAFLD in humans and heavily obese male mice.17 These
markers were upregulated in female DIO mice compared with weight-
matched male DIO mice, suggesting that these markers translate to
























































































































































































Vehicle GIP GLP1 GLP1/GIP
F IGURE 2 Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) improves lipid metabolism with greater
potency in diet-induced obese male and female mice relative to treatment with GIP or GLP-1 alone. A, Plasma cholesterol, B, plasma lipoprotein
fractions, C, total liver weights, D, liver histology and E, lipid area within hepatic sections of male mice, and F, plasma cholesterol, G, plasma
lipoprotein fractions, H, total liver weights, I, liver histology, and J, lipid area within hepatic sections of female mice treated daily with either
vehicle [n (female) = 7, n (male) = 7], acyl-GIP [10 nmol/kg; n (female) = 7, n (male) = 8], acyl-GLP-1 [10 nmol/kg; n (female) = 7, n (male) = 7], or
acyl-GLP-1/GIP [10 nmol/kg; n (female) = 7, n (male) = 8] via subcutaneous injections for 21 days. Blood lipids were determined from sac plasma
in the end of the study. Data represent means ± SEM. A, E, F, *P < .05, **P < .01, ***P < .001, determined by one-way ANOVA followed by Tukey
post hoc multiple comparison analysis to determine statistical significance. D, *P < .05, ***P < .001, determined by Kruskal-Wallis test followed by
Dunn's multiple comparison test to determine statistical significance. HDL, high-density lipoprotein; LDL, low-density lipoprotein
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both sexes. Hence, PPP implies a more pronounced NAFLD pheno-
type in females relative to body weight-matched male DIO mice. Liver
histology revealed increased lipid content in female relative to male
DIO mice, an observation that might be influenced by the different
duration of HFD exposure (32 weeks in females vs. 7 weeks in males)
(Figure 2D and 2I). Taken together, our data demonstrate that the
plasma proteome markedly differs between both sexes with weight-
matched male mice showing a greater level of markers indicative of
inflammation and a less pronounced NAFLD phenotype relative to the
females.
3.4 | Glucagon-like peptide-1/glucose-dependent
insulinotropic polypeptide improves cardiovascular
disease risk profile in male and female mice
To examine the contribution of each individual treatment, we com-
pared the plasma proteome of vehicle-treated mice with that of GIP-,
GLP-1- and GLP-1/GIP-treated mice. Because of the aforementioned
sex differences, we analysed treatment effects on the plasma prote-
ome in a sex-dependent manner.
In male DIO mice, we observed a stronger effect of down-
regulation than upregulation of plasma protein levels after compound
treatment (Figure 3A; a complete list is given in Table S4). There was
no overlap among the upregulated proteins by the different treat-
ments (Figure 3A). Of note, GLP-1/GIP treatment increased plasma
levels of complement C1q C chain (C1qc) and pyruvate kinase (Pkm),
both of which are implicated in the polarization of anti-inflammatory
macrophages.28,29 In line with the observation that treatment with
GIP alone had no effect on body weight (Figure 1A and 1B) and lipid
metabolism (Figure 2A-2E), we see no major changes in the plasma
proteome of male mice treated with GIP relative to vehicle controls
(Figure 3A, 3B and 3D).
We observed the downregulation of only 10 plasma proteins by
GLP-1 treatment compared with 33 proteins that decreased by GLP-
1/GIP treatment (Figure 3A). Thus, the co-agonist treatment induced
a far broader spectrum of plasma protein changes than GLP-1
pointing to additive, so far unknown constructive effects by this com-
binatorial pharmacology approach. Six proteins overlapped between
GLP-1 and GLP-1/GIP treatment in male DIO mice (Figure 3A and 3C).
Among the overlapping proteins, four proteins [histidine-rich glycoprotein





F IGURE 3 Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) resolves systemic inflammation in male
mice. A, Venn diagram of upregulated (left) and downregulated (right) proteins in the plasma of GIP-, GLP-1- and GLP-1/GIP-treated male diet-
induced obese (DIO) mice compared with vehicle-treated male DIO mice (P < .01). B, Heatmap of upregulated and C, downregulated proteins.
Intensities of proteins were log2-transformed and Z-scored to normalize across samples. Proteins involved in different biological processes or
belonging to different classes are indicated by colour. D, Changes of the inflammation status of male DIO mice after treatment with vehicle, GIP,
GLP-1 and GLP-1/GIP. Inflammation status is calculated as the mean of the 16 inflammation proteins that changed after GLP-1/GIP treatment
(including Lrg1). Vehicle, n = 5; GIP, n = 8; GLP-1, n = 7, GLP-1/GIP, n = 8
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peptidoglycan recognition protein 2 (Pglyrp2)] were associated with
inflammatory processes (Figure 3C). Furthermore, Saa1 belongs to the
newly identified NAFLD biomarker panel.17 Interestingly, GLP-1 and
GLP-1/GIP treatment reduced plasma levels of Lrg1, a recently suggested
biomarker for obesity, systemic inflammation and atherosclerosis.30,31
Remarkably, among the 27 proteins more potently reduced exclu-
sively by the GLP-1/GIP co-agonist, we found 11 additional markers
of known implication in inflammatory processes or the complement
system (Figure 3C).
We calculated the mean protein level of all downregulated plasma
proteins by GLP-1 and/or GLP-1/GIP (Figure 3C) as a surrogate of
anti-inflammatory effectiveness. This analysis revealed an anti-
inflammatory effect of GLP-1 and GLP-1/GIP treatment with an addi-
tional effect of the co-agonist to reduce the systemic inflammation
state compared with vehicle and GIP treatment (Figure 3D).
Specifically, co-agonist treatment reduced plasma levels of
serum amyloid A4 (Saa4) and alpha-1-acid glycoprotein 1 (Orm2)
(Figure 3C). Both proteins are associated with an acute phase
reaction upon inflammation.32,33 Blood coagulation factors II (F2),
IX (F9) and XI (F11) as well as plasma regulators of the blood coag-
ulation cascade such as for example the complement component
1 (C1) inhibitor (Serping1), serpin family A member 10 (Serpina10),
carboxypeptidase B2 (Cpb2), carboxypeptidase N (Cpn1) and
mannan-binding lectin-associated serine proteases (Masp2) were
also lower in the GLP-1/GIP-treated male mice (Figure 3C). These
findings are of interest because obesity has been associated with
increases in components of the fibrinolytic and haemostatic sys-
tem in circulation potentially contributing to the increased CV risk
in these individuals.29,34 In addition, GLP-1/GIP treatment
decreased plasma levels of recently suggested biomarkers for CV
disease (CVD): haemoglobin subunit beta-1 (Hbb1), melanoma cell
adhesion molecule (Mcam), cell growth regulator with EF hand
domain protein 1 (Cgref1) and phosphatidylinositol-glycan-
specific phospholipase D (Gpld1).31,35–38 Together with a reduc-
tion of the LDL particle constituents Apoc2, Apoc3 and Apoe
(Figure 3C), these findings highlight the additional, potentially
beneficial effects in treating cardiometabolic disease by the GLP-
1/GIP co-agonist.
Similar to male DIO mice, we observed also in females that the
majority of affected proteins are decreased rather than increased after
compound treatment (Figure 4A; a complete list is given in Table S5).
GIP monotherapy increased circulating lactate dehydrogenase A
(Ldha) levels, a monomeric subunit of lactate hydrogenase, which is a
rate-limiting enzyme in anaerobic glycolysis (Figure 4B). GLP-1 mon-
otherapy increased complement and blood coagulation associated
proteins such as coagulation factor XIII B chain (F13b), coagulation
factor XIII A chain (F13a1) and protein Hc (Hc, also known as
α1-microglobulin) (Figure 4B). The first two proteins belong to the
plasma factor XIII tetramer that catalyses the last step of the blood
coagulation pathway. Among the GLP-1/GIP-regulated proteins, we
found increased plasma levels of platelet factor 4 (Pf4, also known as
C-X-C motif chemokine 4, Cxcl4) and thrombospondin 1 (Thbs1)
(Figure 4B). Thbs1 has been associated to obesity and the metabolic
syndrome, particularly in women.39
GIP, GLP-1 and GLP-1/GIP treatment reduced one, nine and




F IGURE 4 Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) improves metabolic state in female diet-
induced obese (DIO) mice. A, Venn diagram of upregulated (left) and downregulated (right) proteins in the plasma of GIP-, GLP-1- and GLP-1/
GIP-treated DIO mice compared with vehicle treated DIO mice (P < .01). B, Heatmap of upregulated and C, downregulated proteins. Intensities of
proteins were log2-transformed and Z-scored to normalize across samples. Proteins involved in different biological processes or belonging to
different classes are indicated by colour. Vehicle, n = 7; GIP, n = 5 GIP; GLP-1, n = 7; GLP-1/GIP, n = 7 GLP-1/GIP
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(Figure 4A). GIP decreased plasma protein levels of collagen type XVIII
alpha 1 chain (Col18a1), a novel potential biomarker for CVD
(Figure 4C).40 GLP-1 treatment reduced the inflammation-associated
proteins dipeptidase 2 (Dpep2), proteoglycan 4 (Prg4) and proteasome
subunit alpha type-6 (Psma6) (Figure 4C). Five of the GLP-1-regulated
proteins overlapped with proteins downregulated by GLP-1/GIP
treatment (Figure 4A and 4C). Three of these five proteins were asso-
ciated with an improvement of NAFLD (Aldob, Lap3, Me1)
(Figure 4C). An additional 14 proteins pertinent to protein classes
associated with inflammation, coagulation, lipid transport and to novel
biomarkers for NAFLD and CVD were further reduced exclusively by
GLP-1/GIP treatment (Figure 4A and 4C).
3.5 | Sex-independent plasma protein panel
downregulated by glucagon-like peptide-1/glucose-
dependent insulinotropic polypeptide treatment
correlates to systemic metabolic benefits
Although PPP responses after mono-agonist treatment were mainly
different between sexes (Figure S9), we detected 10 plasma proteins
that were decreased in DIO male and female mice after co-agonist
treatment (Figure 5A and 5B). Among these we found: (i) phospholipid
transfer protein (Pltp) and angiopoietin-like protein 3 (Angplt3), which
are both modulators of lipoprotein metabolism, and high plasma levels
are associated with obesity, T2D and CVD in humans41,42; (ii) plasma
apolipoprotein levels of Apoc4 in line with the further decreased LDL
fraction after co-agonist but not mono-agonist treatments (Figure 2B,
G); and (iii) hepatocyte growth factor activator (Hgfac), a serine prote-
ase that converts Hgf to its active form, of which increased levels
have been associated with a more severe progression of atherosclero-
sis indicated by increased numbers of carotid plaques in humans.43
By correlating each of the sex-independent downregulated
10 proteins to physiological parameters determined in this study, we
aimed to find biomarkers that broadly reflect systemic metabolic ben-
efits after weight loss such as after treatment with a clinically advanc-
ing GLP-1/GIP co-agonist. Expectedly, and in agreement with similar
weight-lowering efficacy of GLP-1/GIP treatment in both sexes, each
of the 10 proteins significantly correlated to body weight loss in male
and female mice (Figure 5C). Particularly in male mice, most of these
10 proteins also correlated to improvements in glucose and insulin
homeostasis, lipid metabolism and liver fat area. Apoc4, Hgfac,
Angptl3 and Pltp depicted the strongest overall correlation to GLP-1/





F IGURE 5 Sex-independent plasma proteins correlate with glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/
GIP)-induced metabolic benefits. A, Venn diagram showing the differentially up- and downregulated plasma proteins of diet-induced obese male
and female mice after GLP-1/GIP treatment. B, Heatmap of commonly downregulated proteins in male and female mice after GLP-1/GIP
treatment. Correlation matrix of the 10 sex-independent downregulated proteins to physiological parameters determined in this study of C, male,
and D, female, mice. HOMA-IR, homeostatic model assessment of insulin resistance; ipGTT, intraperitoneal glucose tolerance
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correlation coefficients) (Figure 5C). The correlation coefficients in
female mice were in general lower with no significant correlations to
improvements in glucose and insulin homeostasis (Figure 5D). This is
possibly because of the overall superior metabolic state of female
compared with male mice (Figure S6). As for male mice, Apoc4 had
the strongest overall correlation coefficient in female mice
(Figure 5D).
4 | DISCUSSION
To the best of our knowledge, here we show for the first time that a
balanced GLP-1/GIP monomeric peptide co-agonist has a superior
treatment efficacy and induces a broader spectrum of changes in
plasma proteome relative to treatment with GLP-1 or GIP alone in
both sexes of DIO mice. PPP revealed that co-agonist treatment
improved plasma protein markers suggestive of systemic inflamma-
tion more potently than either monotherapies, particularly in male
DIO mice. Furthermore, our combination of pharmacology and PPP
potentially revealed sex-independent plasma biomarkers that might
enable minimal-invasive monitoring and uncover, ulterior, underlying
mechanisms of systemic metabolic improvements after weight loss
interventions such as the clinically advancing GLP-1/GIP co-
agonists.
GLP-1/GIP lowered body weight with comparable potency in
both sexes. In females, the superior weight loss of GLP-1R/GIPR
co-agonism relative to treatment with GLP-1 was accompanied by an
increased anorectic effect of the co-agonist. However, in male DIO
mice we found that the additional weight-lowering efficacy of the
co-agonist compared with the GLP-1 mono-agonist cannot be
explained solely by reduced energy intake alone. Finan et al. showed
that GLP-1/GIP treatment in DIO male mice does not increase energy
expenditure in male DIO mice, but exceeds pair-feeding induced
weight loss.6 Together, these findings suggest that other mechanisms
could contribute to the body weight-lowering effect of the GLP-1/
GIP co-agonist in male DIO mice, and interestingly, this may differ for
female mice. We found that the ulterior body weight loss of the
co-agonist versus the GLP-1R mono-agonist was slightly greater in
female DIO mice compared with male DIO mice [3.1 g (7.2%) vs. 2.9 g
(5.8%)]. This translated to a mean additional fat mass lost by GLP-1/
GIP co-agonist over GLP-1 mono-agonist treatment of 2.4 and 2.9 g
for male and female mice, respectively. As Benz et al. have recently
shown that female DIO mice respond to weight-lowering interven-
tions with an enhanced lipolytic activity in adipose tissue compared
with male DIO mice,44 we cannot exclude that this inherent sex differ-
ence accounts for the slightly enhanced weight loss in female DIO
mice we observed after GLP-1/GIP treatment. However, as female
DIO mice exhibited a greater fat mass than male DIO mice at the start
of treatment start is also possible that direct effects of GIP on adipo-
cytes45 contributed to the greater separation because of the addi-
tional adipose tissue available. Future studies are warranted to dissect
GIP-dependent mechanisms on adipose tissue in detail. As reported
previously,6 the body weight neutral dose of acyl-GIP applied herein
improves glucose metabolism in male DIO mice and, as shown here, in
female DIO mice.
The comparison of vehicle treated male and female DIO mice
showed substantial differences in the plasma proteome. We detected
markedly increased plasma levels of the complement cascade in male
relative to female DIO mice. This is in line with literature describing a
decreased abundance and activity of complement proteins in the
plasma of female rodents and women compared with male counter-
parts.24,25 Whether a differentially regulated complement system con-
tributes to the protection of female mice against DIO-mediated
complications remains uncertain. Accordingly, we did not observe a
comparably pronounced effect of GLP-1/GIP treatment in reducing
proteins involved in inflammatory processes and immunological
responses in female as compared with male DIO mice. In male DIO
mice, GLP-1/GIP treatment resolved the mild obesity-associated sys-
temic inflammation more potently than both mono-agonists. Although
we cannot exclude that the additional anti-inflammatory phenotype
after GLP-1/GIP co-agonist treatment results from a higher degree of
weight loss, it is conceivable that the direct immunoregulatory effects
of GLP-1 and/or GIP might have contributed.46 In future studies it
would be of specific interest to investigate plasma proteomic changes
induced by caloric restriction and pharmacological treatment that are
matched for body weight loss (e.g. pair-feeding) to test for
compound-specific changes.
In addition to the clinical pilot trial of a PEGylated unimolecular
dual incretin6 and to the phase 2 clinical study with LY3298176, a
novel dual GLP-1/GIP receptor co-agonist from Eli Lilly,5 we showed
in a 12-week proof-of-concept study in humans that a dose of
1.8 mg/day of a sustained-acting fatty-acylated GLP-1/GIP co-
agonist (NNC0090-2746) with balanced activity at each receptor
(GLP-1R EC50 = 5pM; GIPR EC50 = 3pM) reduced body weight and
improved glycaemic control compared with placebo in T2D.4 This
safety study was not designed to assess the body weight- and
glucose-lowering potential of NNC0090-2746 in patients with obe-
sity and/or with T2D. Clearly, to assess completely the metabolic
efficacy of this balanced GLP-1/GIP co-agonist more studies are
needed, including for example a dose-finding trial, a refined escala-
tion schedule and importantly, a trial with longer treatment duration.
However, NNC0090-2746 reduced total plasma cholesterol com-
pared with the placebo control group, whereas the GLP-1 control
(liraglutide; 1.8 mg with a 2-week dose escalation) had no effect
despite similar weight loss compared with NNC0090-2746.4 Here,
we show that only GLP-1/GIP co-agonist treatment significantly
reduced fasting plasma cholesterol levels in male and female DIO
mice. This effect was superior to both mono-agonists and was
accompanied by a striking decrease of LDL lipid fractions in both
sexes. The GIPR is widely expressed on adipocytes. GIP has been
shown in the past to affect white adipose tissue indirectly by increas-
ing adipose tissue blood flow and directly by modulating adipocyte
metabolism.45 The effect of GIP to increase white adipose tissue per-
fusion is blunted in obese humans, but can be reverted by weight
loss.47 GLP-1-induced weight loss could thus prime GIP action on
lipid metabolism contributing to the superior benefits of the GLP-1/
204 SACHS ET AL.
GIP co-agonist compared with its respective mono-agonists. How-
ever, the pharmacological potential of GIP analogues to treat
dyslipidaemia and/or target adipose tissue directly in vivo has not
been entirely tested yet and requires future studies.48 These findings
are further supported by a more potent reduction of plasma apolipo-
proteins pertinent to LDL particles by GLP-1/GIP compared with
GLP-1 in male and female DIO mice as determined by PPP. This
underlines the power of PPP to detect multiple lipid particles in more
depth. The advantage of the proteomic approach is that less plasma
volume is required as for conventional assays and thus makes the
comparison of multiple parameters in preclinical pharmacological
studies possible. Besides apolipoprotein fractions, PPP revealed addi-
tional markers of CVD risk that were reduced particularly after GLP-
1/GIP treatment in male (e.g. Hbb1, Mcam, Cgref1, Hgfac and Gpld1)
and female (e.g. Hgfac) DIO mice. Collectively, the GLP-1/GIP co-
agonist treatment more potently improved the CV risk profile of male
and female DIO mice compared with mono-agonist treated mice. It is
of specific interest to explore potential novel underlying mechanisms
and efficacy of GLP-1R/GIPR co-agonism or either mono-agonism in
future studies in this regard.
NAFLD is the hepatic manifestation of metabolic disease and
shares almost identical risk factors.49 There is no approved pharma-
cological therapy to treat the disease. Therefore, predictive bio-
markers of disease risk and therapy response are urgently needed.49
Niu et al. recently applied PPP to identify novel biomarkers of
NAFLD in mice and humans, which potentially discriminate between
reversible NAFLD and irreversible liver cirrhosis.17 Treatment of
female DIO mice with GLP-1 and GLP-1/GIP reduced plasma levels
of Aldob, Lap3 and Me1 with an additional effect of GLP-1/GIP to
reduce Enpep accompanied by a decreased hepatic lipid content
and an improved hepatic histology. Furthermore, we found
decreased levels of Cd5l in the plasma of DIO female GLP-1/GIP-
treated mice. Plasma Cd5l is higher in women than in men and path-
ologically increased Cd5l levels were found in patients with liver
cirrhosis and proposed as a potential biomarker for assessing liver
fibrosis.50 Altogether, our results not only demonstrate the poten-
tial of these new markers to characterize liver diseases, but also
highlight the potential application of the GLP-1/GIP co-agonist to
treat NAFLD51 and the power of PPP to access treatment responses
cross-species in a systemic way.
Bariatric surgery is still the most effective intervention to correct
obesity and its comorbidities. Combining pharmacology and MS-
based unbiased PPP, we herein show that GLP-1R/GIPR co-agonism
is more effective than either the mono-agonist to reduce body
weight, to improve glucose tolerance, to ameliorate systemic inflam-
mation, to improve dyslipidaemia, to reduce the CVD risk profile and
to reverse liver steatosis in male and female DIO mice. In particular,
PPP revealed superior GLP-1/GIP-mediated downregulation of
inflammatory and lipid-particle associated proteins compared with
either mono-agonist in male and to a lesser extent in female mice.
Inflammatory proteins were the most significantly downregulated
proteins indicative of long-term RYGB success to reduce body
weight in patients with obesity.10 While comparing the similarities of
the anti-inflammatory effect after GLP-1/GIP treatment in mice and
RYGB-treatment in humans, we detected eight overlapping proteins.
Three of these, Saa1, Orm1 and Pglyrp2 were downregulated by both
GLP-1 and GLP-1/GIP co-agonist treatment. However, the levels of
the other five plasma proteins Orm2, Saa4, Masp2, F2 and Serping1
were significantly reduced exclusively by GLP-1/GIP treatment. In con-
trast to male DIO mice, only Pglyrp2 of the RYGB-associated inflam-
mation markers was decreased in plasma of female DIO mice after
GLP-1 and GLP-1/GIP treatment, highlighting previously mentioned
sex-specific differences in the DIO-associated inflammation status
(Figure S8). Taken together our results point to ulterior benefits of our
novel unimolecular co-agonist beyond its respective mono-agonists.
Collectively, our results support the rationale of integrating multiple
hormones to close the gap to metabolic benefits usually achieved only
by surgical intervention.
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